Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:CRBPOTCMKTS:INVVYNASDAQ:NERVNASDAQ:REPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$17.95+0.7%$15.81$9.50▼$18.85$1.63B1.61.21 million shs130,414 shsCRBPCorbus Pharmaceuticals$32.93-1.7%$36.36$3.03▼$49.87$346.09M2.46770,662 shs30,768 shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsNERVMinerva Neurosciences$2.49+2.5%$3.34$2.29▼$13.49$17.41M0.2199,889 shs1,171 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+0.91%+2.53%+9.73%+28.85%+77.49%CRBPCorbus Pharmaceuticals-5.74%-8.29%-7.33%+13.60%+335.63%INVVYIndivior0.00%0.00%0.00%0.00%-5.84%NERVMinerva Neurosciences-2.78%-2.39%-4.67%-69.90%-5.77%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals1.9226 of 5 stars3.51.00.00.03.01.70.6CRBPCorbus Pharmaceuticals4.3356 of 5 stars3.52.00.04.72.53.30.6INVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.618 of 5 stars3.05.00.04.61.80.00.0REPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$22.5725.75% UpsideCRBPCorbus Pharmaceuticals3.00Buy$52.0057.91% UpsideINVVYIndiviorN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$11.00341.77% UpsideREPHRecro PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest AVDL, REPH, CRBP, NERV, and INVVY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/13/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.003/6/2024CRBPCorbus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$4.00 ➝ $46.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.001/29/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $51.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M58.15N/AN/A$0.98 per share18.32CRBPCorbus Pharmaceuticals$880K393.29N/AN/A($1.56) per share-21.11INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AREPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A21.12N/AN/A-198.06%-84.51%5/2/2024 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%5/14/2024 (Estimated)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ANERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)REPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest AVDL, REPH, CRBP, NERV, and INVVY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million 2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36CRBPCorbus PharmaceuticalsN/A0.740.74INVVYIndiviorN/AN/AN/ANERVMinerva NeurosciencesN/A12.5712.58REPHRecro Pharma2.273.242.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CRBPCorbus Pharmaceuticals64.64%INVVYIndivior0.05%NERVMinerva Neurosciences34.56%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%CRBPCorbus Pharmaceuticals4.00%INVVYIndiviorN/ANERVMinerva Neurosciences6.40%REPHRecro Pharma14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionableAVDL, REPH, CRBP, NERV, and INVVY HeadlinesSourceHeadlineDorf Ketal's Indian unit acquires veterinary pharma brandvccircle.com - April 10 at 10:57 PMFuji Pharma Co. Ltd.wsj.com - January 30 at 3:34 PMAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croremoneycontrol.com - November 22 at 10:47 PMRetaining the human element of AI within pharma and healthcarepharmaphorum.com - November 21 at 10:06 AMHere's what Wall Street expects from Recro Pharma's earnings reportmarkets.businessinsider.com - November 7 at 12:00 PMUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitstheguardian.com - August 16 at 1:59 AMMankind Pharma share pricelivemint.com - August 9 at 12:30 PMWhat Wall Street expects from Recro Pharma's earningsmarkets.businessinsider.com - August 9 at 7:25 AMMankind Pharma Ltd (MNKI)investing.com - August 3 at 9:00 AMEversana and Amazon plan generative AI push in pharmapharmaphorum.com - July 30 at 11:21 PMAurobindo Pharma Ltd.ndtv.com - July 25 at 12:39 AMBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsbizjournals.com - June 30 at 12:44 PMPharma reform: Patients can’t afford to wait. Act now.politico.eu - June 13 at 3:41 PMSun Pharma reports "information security incident"; isolates impacted IT assetshealth.economictimes.indiatimes.com - March 9 at 7:26 AMWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLijr.com - March 2 at 12:30 AMAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendmoneycontrol.com - February 17 at 8:43 PMPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusfinancialexpress.com - December 20 at 8:48 AMPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLbenzinga.com - June 24 at 9:08 AMSocietal CDMO Increuters.com - April 20 at 9:24 AMRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformationfinanznachrichten.de - March 22 at 10:51 PMRecro Pharma Rebrands to Societal CDMO Inc.contractpharma.com - March 22 at 5:51 PMIs Recro Pharma (REPH) a Worthy Investment?finance.yahoo.com - March 22 at 8:32 AMRecap: Recro Pharma Q4 Earningsbenzinga.com - March 1 at 11:55 PMRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilitiescontractpharma.com - February 23 at 9:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.